RNA interference (RNAi)-based gene therapy has great potential in cancer and infectious disease treatment to correct abnormal up-regulation of gene expression. We show a new original method uses synthetic microRNAs combined with a thermo-inducible promoter to reduce specific gene expression. The targeted gene is the luciferase firefly reporter gene overexpressed in a subcutaneous tumor which allows the RNAi monitoring by bioluminescence imaging (BLI). The inducible inhibition was first demonstrated in vitro using genetically modified cells lines and then in vivo using the corresponding xenograft model in mice. Achieving spatio-temporal control, we demonstrate the feasibility to induce, in vivo, a specific gene inhibition on demand. Future applications of this RNAi-based gene therapy, which can be restricted to pathological tissue, would offer wide-ranging potential for disease treatment.
DNA constructs. Plasmids pcDNA 6.2 -GW EmGFP-miRLuc and pcDNA 6.2 -GW EmGFP-miRneg were purchased from Invitrogen (BLOCK-iT TM system, Life Technologies TM , Carlsbad, CA, USA). These vectors allowed for co-cistronic expression of the EmGFP (Emerald Green Fluorescent Protein) reporter gene and synthetic miRNA under the transcriptional control of the constitutive CMV promoter. Correlation between EmGFP and miRNA expressions was previously demonstrated (Life Technologies TM ). The pcDNA 6.2 -GW EmGFP-miRLuc encoded a mature synthetic miRLuc specific to the LucF mRNA. pcDNA 6.2 -GW EmGFP-miRneg encoded a mature miRNA called miRneg, unrelated to any known gene and used as a negative control. To increase efficiency of the inhibitory effect of miRNA, 3 additional copies of each pre-miRNA were cloned into the pcDNA 6.2 -GW EmGFP-miRLuc and pcDNA 6.2 -GW EmGFP-miRneg vectors to obtain the pcDNA 6.2 -GW EmGFP-4*miRLuc and pcDNA 6.2 -GW EmGFP-4*miRneg plasmids.
The Hsp70B promoter sequence was excised from pD3SX vector (Stressgen Biotechnologies Corp. Victoria, BC, Canada). Renilla luciferase (LucR) reporter gene was excised from pRL-CMV vector (Promega). By several cloning steps the CMV promoter from pcDNA 6.2 -GW EmGFP-4*miRLuc and pcDNA 6.2 -GW EmGFP-4*miRneg was replaced by a Hsp-LucR-Hsp cassette to obtain pcDNA 6.2 -Hsp-LucR-Hsp-EmGFP-4*miRLuc and pcD-NA 6.2 -Hsp-LucR-Hsp-EmGFP-4*miRneg constructs.
Cell culture and stable transfections. The different U87 cells lines were maintained in Dulbecco's modified Eagle's medium (DMEM; Life Technologies TM ) supplemented with 10% fetal calf serum (Life Technologies TM ), 1% antimycotic-antibiotic mix (PSA; Life Technologies TM ) and 1% non-essential amino-acid (MEM NEAA; Life Technologies TM ) at 37 °C and 5% CO 2 . Cells were subcultured 1:3 by trypsinization upon reaching 90% confluence. The stably transformed U87 CMV-LucF cell 17 was further transformed by either pcD-NA 6.2 -Hsp-LucR-Hsp-EmGFP-4*miRLuc or pcDNA 6.2 -Hsp-LucR-Hsp-EmGFP-4*miRneg using TransFast TM transfection reagent (Promega, Madison, WI, USA) according to the manufacturer's instructions. Stably transformed cells lines miRLuc and miRneg were selected with 2 µg/mL blasticidin (PAA, Piscataway, NJ, USA) and amplified for both in vitro experiments and tumor generation in NOG mice.
In vitro luciferase assays. Firefly and Renilla luciferases enzymatic activities were measured on cells lysates (25,000 cells) using the Dual-Luciferase ® Reporter Assay System (Promega) using a luminometer (LUMAT 9501;
Berthold Technology, Bad Wildbad, DE). Light production was expressed in Relative Light Units (RLU). Table S1 ) (Eurogentec; Seraing, BE). Normalization was performed regarding to 36B4 gene level and the relative expression for a target gene was calculated using the comparative Ct method (2 −ΔΔCt ). Table S2 ). Real time PCR reactions were performed using SYBR ® Geen I dye and specific primers ( Supplementary Table S3 ). The expression level of miRNA was normalized to the small nucleolar RNA RNU44 and the relative expression was calculated using the comparative Ct method (2 −ΔΔCt ). Subcutaneous tumor generation. U87 cell suspension (2 × 10 6 cells; 100 µL PBS) was inoculated into the subcutaneous tissue in the mice using an U-100 insulin syringe (TERUMO ® , Cottontail Lane Somerset, NJ, USA). MiRLuc and miRneg cell lines were injected into hind legs. For this, one tumor per animal was generated, using the left side for the miRLuc cell line and the right side for the miRneg cell line. Once the tumor became palpable, tumor width and length were measured using a digital caliper by the same researcher to prevent Hyperthermia treatment. Cell hyperthermia. Cells were plated 48 hours before the experiment (15,000 cells per well into 4-well plates). Hyperthermia was induced using a water bath (45 °C; 20 min) and the media was renewed using pre-warmed media, then the cells were returned to the incubator at 37 °C and 5% CO 2 .
RNA isolation, reverse transcription and real
Tumor hyperthermia. When tumors reached a volume of 110 ± 80 mm 3 , anesthetized mice were placed on a polystyrene-isolated platform floating on the surface of a water-bath. Mice hind legs were dipped into hot water (45 °C +/− 0.1 °C; 8 min) by a hole in the platform, thus heating only the legs while the rest of the body was lying on the isolation material.
In vivo bioluminescence imaging. BLI was performed at VivOptic (UMS 3767, Bordeaux University, FR) using a Lumina LT system (Perkin Elmer Inc., Boston, MA, USA) including a highly sensitive CCD camera. For LucF signal detection, mice received an intra-peritoneal injection of D-luciferin (Promega, Madison, WI, USA, 2.9 mg in 100 µL PBS) and were sedated 7 min later. For LucR signal detection, mice received an intra-peritoneal injection of ViviRen (Promega, 50.8 µg in 100 µL PBS-BSA 0.1%) and were sedated 17 min later. Bioluminescence images (1 min, 4 × 4 binning) and photographs (100 ms exposure) were taken at 10 min or 20 min after the substrate injection for LucF and LucR respectively. The bioluminescence signal was converted using a false color scale and images representing the spatial distribution of emitted photons were generated using Living Image software (Perkin Elmer Inc.) and superimposed on to the photograph. BLI analysis was performed semi-automatically by placing a small region of interest (ROI) on the leg. The mean light intensity (in photons.s −1 .mm −2 .sr −1 ) was measured within this ROI.
Statistical analyses. All statistical analyses were performed using a two-tailed unpaired Student's t test for comparison of two groups and a statistical difference was considered as *P < 0.05, **P < 0.01 and ***P < 0.001. In the qRT-PCR experiment, the statistical analyses were made on the dCt for more accuracy. All data were represented as mean ± s.e.m.
Results and Discussion
A thermo-inducible inhibition strategy through the Hsp70B promoter. To demonstrate the feasibility of our method, we generated cell lines which constitutively express the LucF reporter gene (CMV promoter) and contained inducible Renilla luciferase (LucR), emerald GFP (EmGFP) and 4 copies of synthetic miRNAs under the Hsp70B transcriptional control (Fig. 1A) . This strategy aimed to control the heat-induction using LucR and EmGFP as reporters and monitoring the effect of the miRNA on the LucF expression in vivo. Furthermore, the separate monitoring of LucF and LucR expressions allowed the distinction between heat-induction and the effect of the synthetic miRNA as these luciferases have their own substrate and show distinct kinetics of light production in vivo. RNAi was assessed by specific synthetic miRNAs (miRLuc) targeting LucF mRNA (Supplementary Figure S4 ) and miRneg (unrelated to any known gene) was used as a negative control. After in vitro validation, we generated subcutaneous tumors in mice to follow heat-induced target gene inhibition by bioluminescence imaging (BLI), involving the non-invasive interrogation of living animals using light emitted from luciferase-expressing cells.
Thermo-induced RNAi in vitro.
In vitro, after a heat shock of the miRLuc and miRneg cell lines, the synthetic miRNAs expressions showed an increase of miRLuc and miRneg miRNAs levels 6 hours after treatment (Fig. 1B) . To control the Hsp70B promoter activation after a short and transient heat shock of miRLuc and miRneg cell lines, LucR and EmGFP expression were followed using enzymatic assays and flow cytometry respectively ( Fig. 1C and D respectively). Our data shows low basal activity for LucR and EmGFP. A maximal level of activation was reached 6 hours after hyperthermia for the two reporter proteins in both cells lines, thus suggesting an early activation of Hsp70B promoters in accordance with the literature. Interestingly Fig. 1D showed a difference in EmGFP kinetics between cell lines which prompted us to not use this reporter as an internal control for the subsequent experiments. Additionally, we measured the endogenous Hsp70 pathway which showed a transient induction of Hsp70 mRNAs expression (transcripts resulting from the transcription driven by all the Hsp70 promoters) (Supplementary Figure S5 ). Although Hsp70B promoter was described to exhibit a relatively low basal activity, as shown in Fig. 1 , our data demonstrated the efficiency of the Hsp70B-induced promoter activation by hyperthermia in vitro. This allowed us to pursue further investigations on miRLuc efficiency. We investigated whether miRLuc impacted on LucF mRNA content and LucF activity in the miRLuc cell line ( Fig. 2A and B respectively, both normalized to miRneg cell line). Our results showed a 50% decrease in LucF mRNA content expression 6 hours following hyperthermic miRLuc expression induction by hyperthermia which was sustained for 24 hours before returning to normal levels two days post-treatment ( Fig. 2A) . This result showed the efficiency of the synthetic miRNA on the degradation of its mRNA target. Furthermore, outcomes of this repression were delayed in time for LucF activity. LucF activity showed a minimum 50% decrease one to two days following miRLuc induction by heat treatment (Fig. 2B) . Overall, in vitro experiments validated the thermo-induced RNAi strategy.
In vivo gene inhibition via Hsp70B-induced miRNA expression.
To generate xenograft tumors, miRLuc and miRneg cell lines were injected subcutaneously in immunodeficient mice legs. The constitutive expression of LucF enabled tumor growth monitoring by BLI. In vivo hyperthermia was performed by bathing mice legs in a water-bath (45 °C; 8 min). LucR expression was then monitored to control hyperthermia efficiency (Fig. 3A) . In accordance with our in vitro observation, the LucR bioluminescent signal was detected 6 hours after Scientific REPORTS | (2018) 8:4694 | DOI:10.1038/s41598-018-22932-3 hyperthermia in both tumors. Synthetic miRNA contents and Hsp mRNA were quantified by qRT-PCR in tumor samples at different time points after hyperthermia ( Fig. 3B and Supplementary Figure S6 respectively) . The profile obtained for Hsp mRNA expression after hyperthermia in vivo was transient with a maximum at 6 hours as observed in vitro (Supplementary Figure S5) for the two cell lines. Furthermore, our data showed the induction of the synthetic miRNAs expression in vivo. These results confirmed the suitability of our heating method to induce Hsp70B promoters in vivo. Previous studies by others in mammalian cells showed a half-life of LucF of 3 hours 19, 20 and we previously measured a half-life of around 20 hours in an in vivo mouse model 21 . It is important to note that this half-life enables the measurement of any dynamic changes in LucF reporter transcription level in vivo. Subsequently, the effectiveness of miRLuc to reduce LucF expression was investigated by BLI monitoring. The time courses of LucF activity as well as the measurement of tumor growth were followed on both miRLuc and miRneg tumors from day one (beginning of the effect observed in vitro; Fig. 2B ) to two days after hyperthermia. The BLI/tumor size ratio between the different time points after hyperthermia was calculated for miRneg and miRLuc tumors (Fig. 4) . Our data shows a significantly higher reduction of the BLI/tumor ratio for the miRLuc tumor compared to miRneg after hyperthermia. This result corroborated our first in vitro observations and showed, in vivo, the efficiency of the heat-induced miRNA on its target gene.
Conclusion
This study describes the utilization of a Hsp-controlled RNAi system in which a conditional synthetic miRNA was specifically designed to silence a reporter gene in vivo. We demonstrated the feasibility of on demand heat-triggered gene inhibition to ensure spatio-temporal control of gene inhibition in vivo. This method represents a new strategy that experts from different fields could use to address biological questions from their specific topics. For example, in the cancer field, it is well established that cell transformation is caused by multiple gene dysregulation (e.g. oncogenes). In such a pathological context, this new method could demonstrate its applicability to cancer treatment by targeting specific oncogenes in patient tumors. Indeed, we showed that several Hsp-driven transgenic expressions could be induced simultaneously including a mix of genes (two in the present work) and miRNAs (currently 4 copies) providing a way for multiple targeted regulation. But to achieve this goal, strategies will have to be developed to efficiently and specifically deliver to the tumor such synthetic miRNAs. The transient nature of our new method associated with engineered viruses or naked acid nucleic approaches may be promising to achieve gene inhibition while minimizing systemic toxicity. Finally, for this method, the activation of the Hsp70B promoter in vivo was accomplished using a water-bath which conferred the advantage of being a simple and low-cost system to induce hyperthermia on the entire tumor. More clinically relevant heating sources such as focal magnetic resonance-guided high-intensity focused ultrasound 10, 16 could be adapted to the Hsp-controlled RNAi system to reach deep tissues and to have a more precise spatial control.
The method demonstrated in this study offers multiple opportunities in terms of application, while also proposing a useful tool to measure efficiency of the inhibitory action of specific miRNA(s) on tumor cell proliferation monitored by BLI. Figure 4 . In vivo monitoring of thermo-induced silencing. Subcutaneous xenografts were generated by the injection of miRLuc or miRneg cell lines in mice hind legs. The BLI of LucF activity was measured in heatinduced miRLuc and miRneg tumors. The graph represents the BLI/tumor size ratio after hyperthermia corrected to before heat induction (n = 9 per group) (Student's t-test between the two groups on the area under the curve, *p < 0.05).
